To order this 530+ page report, which features160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Key Market Insights
§ Eminent representatives from biopharmaceutical companiesconfirm the rising interest in the concept of subcutaneous drug delivery,highlighting some of the key drivers and upcoming trends in this domain
§ More than 100 subcutaneous biologics have been approved andover 350 such drug candidates are being evaluated in the clinical stages ofdevelopment, for the treatment of a wide variety of disease indications
§ Antibodies and protein therapeutics represent the majorityof subcutaneous biologics that are available / under investigation, designedfor use against various therapeutic areas and having different dosing regimens
§ Advances in drug delivery have led to the development ofnovel technology platforms, enabling the administration of highly viscousformulations, and supporting the development of subcutaneous dosage forms
§ Several technology developers have out-licensed theirproprietary platforms to pharmaceutical companies in order to enable them todevelop subcutaneous formulations of their approved / pipeline products
§ The increasing interest in this field is reflected in the yearlygrowth in partnership activity, including a number of licensing and productdevelopment deals related to subcutaneous formulations of various drugcandidates
§ There are several new and innovative drug delivery systemsthat facilitate subcutaneous administration; we identified over 300 suchsystems that are presently available / under development
§ With several self-medication enabling devices, such aswearable injectors and autoinjectors, available in the market, developers areactively differentiating their offerings by incorporating advanced,patient-friendly features
§ The market is anticipated to be worth over USD 180 billionin 2030; the projected opportunity is likely to be distributed across varioustypes of molecules that are developed / being developed for different diseaseindications
§ Pre-filled syringes continue to dominate the current marketof subcutaneous drug delivery systems; technology developers are expected tocontinue relying on licensing agreements as their primary source of revenues333
For more information,please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html oremail sales@rootsanalysis.com
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
